Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal

Executive Summary

Three antibiotics in just over a week have impressed in Phase III trials, with Tetraphase, The Medicines Company and Paratek all confident of being on the market in the next year

You may also be interested in...



Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala

The latest drug development news and highlights from our US FDA Performance Tracker.

Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move

Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.

14 Approvals To Look Out For In Q3

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel